Published in Neurology on October 01, 1996
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol (2013) 0.99
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol (2005) 0.95
Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci (2013) 0.91
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol (2007) 0.89
Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol (2010) 0.88
Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. BMC Neurol (2009) 0.87
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol (2007) 0.87
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis. Ther Adv Neurol Disord (2013) 0.87
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol Sci (2013) 0.87
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics (2009) 0.85
A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol (2007) 0.83
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord (2011) 0.82
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. Neuropsychiatr Dis Treat (2013) 0.80
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol (2007) 0.80
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. J Neurol (2005) 0.80
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis. Eur J Clin Pharmacol (2015) 0.78
Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol (2003) 0.78
Neutralizing antibodies against interferon-Beta. Ther Adv Neurol Disord (2008) 0.78
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies. Adolesc Health Med Ther (2010) 0.77
The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels. J Interferon Cytokine Res (2009) 0.77
Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. Neurol Sci (2011) 0.76
Serum Lipid Profile Changes Predict Neurodegeneration in Interferon-B1a Treated Multiple Sclerosis Patients. J Lipid Res (2016) 0.75
Assessing cost-effectiveness in the management of multiple sclerosis. Clinicoecon Outcomes Res (2009) 0.75
Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurol (2014) 0.75
Treatment of multiple sclerosis with interferon beta-1 b. Neurology (1997) 0.75
Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2. Pharmaceuticals (Basel) (2010) 0.75
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Ther Adv Neurol Disord (2016) 0.75
Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB) Neurology (1996) 0.75
Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. J Neurol (2016) 0.75
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. Eur J Clin Pharmacol (2016) 0.75
Optimising MS disease-modifying therapies: antibodies in perspective. J Neurol (2004) 0.75
Is multiple sclerosis a disease that requires frequent beta interferon dosing? J Neurol (2004) 0.75